OMIDRIA changes the approach to intraoperative miosis and postoperative ocular pain^1-4

OMIDRIA Mechanism of Action

The two active pharmaceutical ingredients in OMIDRIA, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis. Postoperative pain is also reduced.

Ketorolac
Ketorolac is a non-steroidal anti-inflammatory that inhibits both COX-1 and COX-2, resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma.

By inhibiting prostaglandin synthesis secondary to ocular surgical insult or direct mechanical stimulation of the iris, ketorolac also prevents surgically induced miosis.

Phenylephrine
Phenylephrine is an α1-adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris.

Learn about the OMIDRIA safety profile

REFERENCES: 1. OMIDRIA [package insert]. Bellevue, WA: Rayner Surgical Inc. 2023. 2. Donnenfeld ED, Shojaei RD. Effect of intracameral phenylephrine and ketorolac 1.0%/0.3% on intraoperative pain and opioid use during cataract surgery. Clin Ophthalmol. 2019;13:2143-2150. 3. Schechter BA. Use of topical bromfenac for treating ocular pain and inflammation beyond cataract surgery: a review of published studies. Clin Ophthalmol. 2019;13:1439-1460. 4. Zhu L, Zhang Y, Guo Z, Wang M. Cardiovascular biology of prostanoids and drug discovery. Arterioscler Thromb Vasc Biol. 2020;40(6):1454-1463.

INDICATIONS AND USAGE

OMIDRIA® is added to ophthalmic irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain.

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

Please see the Full Prescribing Information for OMIDRIA.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.